Skip to main content

Table 9 Summary of adverse drug reaction incidence

From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Parameter

120 μg

240 μg

Placebo

Number of patients evaluated

36

41

35

Number of patients who experienced ADR

7 (19.4 %)

13 (31.7 %)

5 (14.3 %)

Number of patients who experienced serious ADR

2 (5.6 %)

0 (0.0 %)

0 (0.0 %)

Number of patients who discontinued the study treatment due to ADR

3 (8.3 %)

5 (12.2 %)

0 (0.0 %)

Number of patients who interrupted the study treatment due to ADR

0 (0.0 %)

1 (2.4 %)

0 (0.0 %)

  1. (): Incidence rate